Cochrane Abstracts
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Irinotecan Chemotherapy Combined With Fluoropyrimidines Versus Irinotecan Alone for Overall Survival and Progression‐free Survival in Patients With Advanced And/or Metastatic Colorectal Cancer." Cochrane Abstracts, John Wiley & Sons, Inc, 2024. Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/432371/all/Irinotecan_chemotherapy_combined_with_fluoropyrimidines_versus_irinotecan_alone_for_overall_survival_and_progression‐free_survival_in_patients_with_advanced_and_or_metastatic_colorectal_cancer.
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer. Cochrane Abstracts. John Wiley & Sons, Inc; 2024. https://evidence.unboundmedicine.com/evidence/view/Cochrane/432371/all/Irinotecan_chemotherapy_combined_with_fluoropyrimidines_versus_irinotecan_alone_for_overall_survival_and_progression‐free_survival_in_patients_with_advanced_and_or_metastatic_colorectal_cancer. Accessed December 8, 2024.
Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer. (2024). In Cochrane Abstracts. John Wiley & Sons, Inc. https://evidence.unboundmedicine.com/evidence/view/Cochrane/432371/all/Irinotecan_chemotherapy_combined_with_fluoropyrimidines_versus_irinotecan_alone_for_overall_survival_and_progression‐free_survival_in_patients_with_advanced_and_or_metastatic_colorectal_cancer
Irinotecan Chemotherapy Combined With Fluoropyrimidines Versus Irinotecan Alone for Overall Survival and Progression‐free Survival in Patients With Advanced And/or Metastatic Colorectal Cancer [Internet]. In: Cochrane Abstracts. John Wiley & Sons, Inc; 2024. [cited 2024 December 08]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/432371/all/Irinotecan_chemotherapy_combined_with_fluoropyrimidines_versus_irinotecan_alone_for_overall_survival_and_progression‐free_survival_in_patients_with_advanced_and_or_metastatic_colorectal_cancer.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression‐free survival in patients with advanced and/or metastatic colorectal cancer
ID - 432371
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/432371/all/Irinotecan_chemotherapy_combined_with_fluoropyrimidines_versus_irinotecan_alone_for_overall_survival_and_progression‐free_survival_in_patients_with_advanced_and_or_metastatic_colorectal_cancer
PB - John Wiley & Sons, Inc
DB - Evidence Central
DP - Unbound Medicine
ER -
